Health supplement melasma removal function testing provides scientific substantiation for skin-brightening and hyperpigmentation-reduction claims through standardized human clinical trials, in vitro efficacy assays, and comprehensive safety evaluation. Accredited third-party laboratories conduct these assessments in accordance with national health food function evaluation guidelines and ISO/IEC 17025 quality management systems, supporting product registration, claim substantiation, and regulatory compliance.
Technical Overview
Melasma (also known as chloasma) is a chronic, acquired hyperpigmentation disorder characterized by symmetric light- to dark-brown macules, most commonly distributed over the malar eminences, forehead, chin, and upper lip. Its pathogenesis involves ultraviolet exposure, hormonal fluctuation, genetic predisposition, and oxidative stress, all of which upregulate tyrosinase activity and melanogenesis within epidermal melanocytes. Because melasma is a human-specific pigmentary condition, the functional evaluation of health supplements claiming to reduce or remove melasma relies primarily on controlled human trials supported by laboratory testing.
The evaluation framework for melasma-removal function claims is built on two pillars: substantiation of efficacy and demonstration of safety. Efficacy is established through human feeding trials with dermatological and instrumental endpoints, while safety is confirmed through physical examination, hematology, clinical biochemistry, and physicochemical and microbiological quality testing in accordance with the national health food safety standard GB 16740. In vitro mechanistic assays, such as tyrosinase inhibition and intracellular melanin quantification, are used to support formulation screening and mechanism-of-action documentation.
- Efficacy substantiation through controlled human feeding trials
- Instrumental measurement of lesion area, pigmentation depth, and skin tone
- Safety surveillance through clinical laboratory indicators
- Physicochemical, contaminant, and microbiological quality verification
- Optional in vitro mechanistic assays for research and labeling support
Testing Samples
Finished Oral Dosage Forms
Representative samples are drawn from commercial production batches and include tablets, hard and soft capsules, granules, effervescent powders, oral liquids, and jellies. Sample handling follows chain-of-custody procedures within ISO/IEC 17025-accredited laboratory systems to ensure traceability from receipt through final reporting.
Active Ingredients and Botanical Extracts
Common test materials include vitamin C, vitamin E, grape seed proanthocyanidins, licorice root extract, green tea catechins, pearl powder, collagen peptides, soy isoflavones, and blended botanical extracts. These ingredients are evaluated for identity, content consistency, and contribution to the overall efficacy profile of the finished product.
Stability and Retention Samples
Batch-consistency and stability samples stored under accelerated and long-term conditions are tested to confirm that the functional actives remain within specification throughout the claimed shelf life, providing supporting data for the registration dossier.
Placebo Preparations
Sensory-matched placebo products, identical in appearance, flavor, and packaging to the test article but lacking the functional actives, are prepared for double-blind clinical trial conduct.
Testing Items
Efficacy and safety testing for melasma-removal claims covers the following core indicators:
- Total area of melasma lesions, expressed in square centimeters, measured by calibrated image analysis
- Pigmentation severity grading scored by dermatological assessment
- Lesion melanin index determined by narrow-band reflectance spectroscopy (mexametry)
- Colorimetric L* values indicating skin brightness at lesion and perilesional sites
- Standardized digital imaging under controlled lighting for objective documentation
- Overall effective rate, defined as the proportion of subjects achieving predefined improvement thresholds
- Safety indicators: physical examination, blood pressure, complete blood count, urinalysis, hepatic markers (ALT, AST, total bilirubin), renal markers (urea nitrogen, creatinine), fasting glucose, and blood lipids
- Quality indicators: heavy metals (lead, arsenic, mercury, cadmium) and microbiological limits per the national health food hygiene standard GB 16740
- Optional mechanistic items: tyrosinase inhibition rate, intracellular melanin content, and antioxidant capacity
Testing Methods
Human Clinical Feeding Trial
The pivotal study is a randomized, double-blind, placebo-controlled parallel-group trial conducted with ethics committee approval and written informed consent, in accordance with the Declaration of Helsinki. Typical subjects are adult volunteers with dermatologist-confirmed melasma; common exclusion criteria include pregnancy or lactation, use of photosensitizing or skin-lightening medication, recent laser or chemical peel treatment, and severe hepatic or renal disease. Subjects consume the recommended daily intake of the test article for 30 to 90 days while maintaining consistent photoprotection habits, with assessments performed at baseline, midpoint, and endpoint.
Instrumental Skin Measurements
Lesion area is quantified through standardized digital photography and calibrated image-analysis software. Pigmentation depth is measured objectively using narrow-band reflectance spectroscopy for the melanin index and tristimulus colorimetry for L* brightness values. All measurements are performed under controlled environmental conditions by trained operators to minimize variability.
In Vitro Efficacy Assays
Mechanistic screening employs a spectrophotometric tyrosinase assay based on L-DOPA oxidation, quantification of melanin content in cultured mouse melanocyte cell lines after alkaline solubilization, and cell viability assessment to confirm that observed melanin reduction occurs at non-cytotoxic concentrations. Radical-scavenging assays such as DPPH and ABTS may be added to document antioxidant contribution.
Safety and Quality Testing
Heavy metal analysis is performed by atomic absorption or inductively coupled plasma mass spectrometry following the GB 5009 series of national analytical standards, and microbiological examination follows the GB 4789 series. Combined with the clinical safety surveillance data, these results substantiate the overall safety profile required for the function claim.
Applications
Testing outcomes serve multiple regulatory and commercial purposes across the product life cycle:
- Registration and filing dossiers supporting melasma-improvement function claims for health food authorities
- Formulation screening, dose optimization, and ingredient comparison during research and development
- Substantiation of advertising and e-commerce claims to reduce regulatory and consumer-protection risk
- Batch release, post-market surveillance, and quality consistency verification
- Import and export compliance documentation for cross-border market access
- Clinical evidence generation for scientific publications and technical marketing materials
FAQ
Are animal experiments required for a melasma-removal function claim?
No. Because melasma is a pigmentary condition specific to humans, the decisive evidence comes from human feeding trials. In vitro assays are used as supplementary mechanistic support and for formulation screening before clinical evaluation.
How long does the complete evaluation take?
Typical timelines range from three to five months, comprising sample receipt and preparation, a 30-to-90-day intervention period, safety follow-up, laboratory analysis, and final report issuance.
What sample quantities are needed?
Generally, samples from three production batches are required, with sufficient units to cover the full trial duration for the enrolled population plus reserve amounts for physicochemical, microbiological, and retention testing.
What defines a positive functional result?
A positive result requires a statistically significant reduction in lesion area and/or pigmentation depth compared with baseline and the control group, achievement of the predefined effective rate threshold, and the absence of adverse events attributable to the test article.
Do accredited third-party laboratories follow recognized quality systems?
Yes. Reputable laboratories operate under ISO/IEC 17025 management systems, conduct trials with independent ethics approval, and apply national analytical standards such as the GB 5009 and GB 4789 series for quality testing.